

## **Mart Saarma patents and patent applications**

### GRANTED PATENTS

1. Saarma, M., Lauren, J., Lindholm, P., Timmusk, T., Tuominen R - Neurotrophic factor protein and uses thereof. US patent issued with the number 7,452,969 on November 18, 2008.
2. Saarma, M. Laurikainen, A. M., Hiltunen J. O., Airaksinen M. S. Klinge E. M. - Neurotrophic factors in the treatment of nerve dysfunctions in the pelvic area (3225): Australia (AU776275), New Zealand (NZ51537), (European Patent. EP 1 181 042 B1).
3. Airaksinen, M., Saarma, M., Poteriaev, D., Lindahl, M., Timmusk, T., Rossi, J. - Compounds related to or derived from GFRalpha4 and their use (3230): Australia (AU782897), Europe, registered in UK, Ireland, Germany, Switzerland (EP1257581)
4. Ibañez CF, Arumäe U, Sariola H, Suvanto P, Trupp M, and Saarma M - Glial cell line derived neurotrophic factor receptors (GFRalpha2) (3256): New Zealand (NZ324511, NZ336245, NZ501199), Australia (AU741208, AU718979), USA (US6696259)
5. Titievsky A, Poteriaev D, Arumäe U, and Saarma M - Ret-independent signaling pathway for GDNF (3266): USA (US6905817)
6. Ibañez CF, Arumäe U, Sariola H, Suvanto P, Trupp M, and Saarma M – GDNFR-beta as an accessory protein for GDNF family ligands: USA (98/09056)
7. Ibañez CF, Arumäe U, Sariola H, Suvanto P, Trupp M, and Saarma M - Glial cell line-derived neurotrophic factor receptors: New Zealand (501199)
8. Ylikoski J, Pirvola U, Saarma M, Walton KM, and Hudkins RL. - Methods preventing/treating damage to sensory hair cells and cochlear neurons: USA (6,448,283)
9. Saarma, M., Kelve M., Truve E., Teeri, T.- Reconstitution of multiple virus resistance in transgenic plants: Austria (AU 669130), USA (5589625), EP92920421
10. Sariola, H., Sainio, K., Suvanto, P., Arumäe, U., Lindahl, M. & Saarma, M. - Glial Cell-Line Derived Neurotrophic Factor Ureteric Budding and Growth: USA (5,882,923).
11. Karelson M, Saarma M, Pilv M Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease. US Patent US 7,786,292 B2. Aug.31, 2010.
12. Saarma M, Karelson M, Pilv M, Bernalov MM. Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signalling pathway activators European Patent No 10790954.1-2101, 2012.
13. Penn R, Runeberg-Roos P, Bernalov MM, Saarma M. Neurturin molecules, US Patent 8,445,432. May 21, 2013.
14. Saarma M, Lindholm P, Voutilainen M, Peranen J, Tuominen R, Airavaara M, Leppanen V-M, Lindahl M, Andressoo JO (2014). Neurotrophic factor MANF and uses thereof. US Patent 8,853,166. October 7, 2014.
15. Saarma M, Karelson M, Bernalov M, Pilv M. Methods facilitating neuronal survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators. US Patent No 8,901,129, December 2, 2014.
16. Nevalaita L, Saarma M. Splice variants of GDNF and uses thereof. European Patent, positive decision to 12 189 585.8-1456, April 20, 2015.
17. Saarma M, Karelson M, Bernalov M, Pilv M. Methods facilitating neuronal survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators. European Patent, No 2509953, issued 7.03.2016 and published in the European Patent Bulletin on 30.03.2016.

18. Saarma M, Pulkkila P, Voutilainen M, Peranen J, Tuominen R, Airavaara M, Leppanen VM, Lindahl M, Andressoo JO. Neurotrophic factor MANF and uses thereof. United State Patent US 9,592,270 B2, March 14, 2017.

## PATENT APPLICATIONS

1. Arumäe U., Runeberg-Roos, P. and Saarma, M. Treatment with a pharmaceutical composition comprising MANF2 nucleic acid. US patent application number: 13/088,233. Filing date: 15.04.2011.
2. Saarma, M. and Andressoo J-O. A transgenic knockout animal comprising a heterozygous or homozygous deletion or a functional deletion of the gene's native 3'UTR, a method for producing such animals, and uses of said animals. US patent application number: 61/506,803. Filing date 12.07. 2011.
3. Saarma, M., Lauren J., Lindholm, P., Timmusk T, Tuominen, R. Treatment with pharmaceutical composition comprising MANF2 nucleic acid. Application number: US 201113088233. Filing date 13.10. 2011.
4. Saarma, M, Karelson, M, Pily, M. Bespalov, M.M. Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signalling pathway activators European Patent No 10790954.1-2101, 2012
5. Arumäe U, Runeberg-Roos, P and Saarma M. MANF/CDNF peptides. (PCT/FI2012/050859 (5.9.2012)).
6. Andressoo J-O, Saarma, M. A transgenic animal comprising a deletion or functional deletion of the 3'UTR of an endogeneous gene. PCT/FI2012/050695, filing date 2012.06.29.
7. Lindahl M, Danilova, T, Palm E, Pulkkila P, Rossi J & Saarma M. (2013) Gene therapy vectors encoding a MANF or CDNF polypeptide for use in the intrapancreatic treatment of pancreatic beta cells. Finnish patent application No 20135577, 28 May, 2013.
8. Saarma M, Voutilainen MH, Airavaara M, Yu LY, Lindahl M. CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof. Filing date: 4.5.2017 Filing country: Finland Filing number: FI 20175392
9. Saarma M, Voutilainen MH, Airavaara M, Yu LY, Lindahl M. C-terminaaliset CDNF- ja MANF-fragmentit, niitä käsittävät farmaseuttiset koostumukset ja niiden käytöt. Filing data 21.06.2018.Filing number: FI 20185304.
10. Huttunen H, Airavaara M, Saarma M. (2019) COMPOSITIONS COMPRISING CDNF OR MANF FOR USE IN THE INTRANASAL TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES United States Patent Application: US 2019 / 0192629 A1, June 27, 2019
11. Mart Saarma, Mikko Airavaara, Merja Voutilainen, Li Ying Yu, Maria Lindahl (2020) C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof. US20200071372A1; United States 2020-03-05, Publication of US20200071372A1 (priority 2017-05-04 Priority to FI20175392
12. Saarma M, Ivanova L, Karelson M, Kovaleva, V. Compounds regulating transmembrane receptors for use in the treatment of disorders. Filed 31.5.2023, Application number FI 20235612.